Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

Medicin og biovidenskab

• BAY 94-8862 100%
• Chronic Renal Insufficiency 46%
• Type 2 Diabetes Mellitus 37%
• Cardiovascular Diseases 25%
• Placebos 16%
• Renin-Angiotensin System 8%
• Heart Failure 5%
• Incidence 5%
• Mineralocorticoid Receptor Antagonists 5%
• Hyperkalemia 4%
• Preexisting Condition Coverage 4%
• Kidney 4%
• Diabetic Nephropathies 4%
• Kidney Diseases 4%
• Glomerular Filtration Rate 3%
• Renal Insufficiency 3%
• Albumins 3%
• Disease Progression 3%
• Creatinine 3%
• Hospitalization 2%
• Myocardial Infarction 2%
• Urine 2%
• Stroke 2%
• Therapeutics 2%